International Journal of Hematology

Papers
(The TQCC of International Journal of Hematology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
COVID-19-associated coagulopathy and disseminated intravascular coagulation245
Changes of hematological and immunological parameters in COVID-19 patients90
Recent advances in the research and management of sepsis-associated DIC45
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine37
Engineering the next generation of CAR-NK immunotherapies36
The human spleen as the center of the blood defense system35
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia30
Multiple myeloma with high-risk cytogenetics and its treatment approach29
Severe immune thrombocytopenic purpura in critical COVID-1925
Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera24
Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia22
New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination22
Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies22
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN)21
Immune thrombocytopenia in a patient with COVID-1921
Characterization of hereditary red blood cell membranopathies using combined targeted next-generation sequencing and osmotic gradient ektacytometry20
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X19
Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan18
Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical 18
Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retr18
Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation18
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment18
Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation17
Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia17
Progressive multifocal leukoencephalopathy after CAR T therapy17
COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm16
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?16
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR us16
Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma15
Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors15
Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-1915
A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 201915
Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children15
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial15
Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis14
Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study14
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study14
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia13
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation13
Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations13
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation12
Genetic landscape of chronic myeloid leukemia12
Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan12
A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma12
Antibody response to COVID-19 vaccination in patients with lymphoma12
Clinical features of 35 Down syndrome patients with transient abnormal myelopoiesis at a single institution11
Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature11
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities11
Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience11
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients11
Risk factors for high-dose methotrexate-induced nephrotoxicity11
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML)11
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-1911
Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants: a matched case–control study11
Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells11
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives11
Diversity of disseminated intravascular coagulation and selection of appropriate treatments11
Platelet indices as a predictive marker in neonatal sepsis and respiratory distress in preterm prelabor rupture of membranes11
Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan11
Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients10
FLT3-targeted treatment for acute myeloid leukemia10
T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia10
Current status and novel strategy of CML10
The mutual crosstalk between iron and erythropoiesis10
Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation10
A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo10
High incidence of venous thrombosis in patients with moderate-to-severe COVID-199
Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease9
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-199
Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome9
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study9
Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study9
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblasti9
Characteristics and transplant outcome of myeloid sarcoma: a single-institute study9
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia9
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial9
Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents9
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis9
Prevalence and molecular spectrum of α- and β-globin gene mutations in Hainan, China9
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation9
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody9
Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis8
Interferon therapy for pregnant patients with essential thrombocythemia in Japan8
Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group8
Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility8
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data8
Patient’s age and d-dimer levels predict the prognosis in patients with TAFRO syndrome8
Clostridium perfringens sepsis in three patients with acute leukemia and review of the literature8
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies8
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma8
A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia8
Expression of activated integrin β7 in multiple myeloma patients8
Anakinra for the treatment of adult secondary HLH: a retrospective experience8
Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis8
Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan8
Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation8
Validation of sepsis-induced coagulopathy score in critically ill patients with septic shock: post hoc analysis of a nationwide multicenter observational study in Japan8
A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation8
Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?8
Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review7
Current insights into the treatments of severe aplastic anemia in China7
Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study7
Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura7
Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia7
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study7
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study7
Effect of hypofibrinogenemia on obstetrical disseminated intravascular coagulation in Japan in 2018: a multicenter retrospective cohort study7
The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia7
Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience7
Megakaryocytes in peripheral blood smears of non-hematological diseases7
Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual7
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria7
Donor-derived myelodysplastic syndrome after allogeneic stem cell transplantation in a family with germline GATA2 mutation7
Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis7
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost7
Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study7
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China7
Bullous pemphigoid is a common associated disorder with acquired haemophilia A7
HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders7
Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors7
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma7
Bringing mass spectrometry into the care of patients with multiple myeloma7
Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD6
Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection6
Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan6
Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan6
Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy6
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study6
Cardiovascular risk factors among adult patients with haemophilia6
Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis6
Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day6
Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells6
The role of epigenetics in T-cell lymphoma6
Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis6
Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen6
Plasma proteomics associated with autoimmune coagulation factor deficiencies reveals the link between inflammation and autoantibody development6
Treatment-free remission and immunity in chronic myeloid leukemia6
Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes6
Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma6
Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study6
Early central nervous system relapse of monomorphic epitheliotropic intestinal T-cell lymphoma after cord blood transplantation6
Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer6
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine6
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting6
Limbic encephalitis with antibodies to N-methyl-d-aspartate (NMDA)-type glutamate receptor after allogeneic transplantation6
Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study6
Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning6
Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series6
Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: resu6
Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection6
An analysis of oral microbial flora by T-RFLP in patients undergoing hematopoietic stem cell transplantation6
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pi5
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma5
Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma5
Effectiveness of hyperbaric oxygen therapy for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation5
Comparison of molecular structure and fibrin polymerization between two Bβ-chain N-terminal region fibrinogen variants, Bβp.G45C and Bβp.R74C5
Virus-infected peripheral blood plasmablasts in a patient with severe fever with thrombocytopenia syndrome5
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3–ITD-mutated acute myeloid leukemia5
Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes5
Cutaneous manifestations of B-cell chronic lymphocytic leukemia5
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial5
Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review5
Optimization of lymphapheresis for manufacturing autologous CAR-T cells5
Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes5
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China5
Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial5
Development of diffuse large B-cell lymphoma from duodenal type follicular lymphoma: a retrospective study of 23 cases5
Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis5
Novel treatments for myelofibrosis: beyond JAK inhibitors5
Incidence, risk factors, and recognition of pseudohyperkalemia in patients with chronic lymphocytic leukemia5
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin5
The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse5
All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 165
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients5
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis5
Aberrant splicing due to a novel RPS7 variant causes Diamond-Blackfan Anemia associated with spontaneous remission and meningocele5
Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation5
Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study5
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration5
Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease5
Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma5
Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy5
Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide5
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma5
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease5
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis5
Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era5
CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation5
Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome5
Resilient T-cell responses in patients with advanced cancers5
Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma5
Next-generation CAR T cells to overcome current drawbacks5
Bone marrow transplantation from a human leukocyte antigen-mismatched unrelated donor in a case with C1q deficiency associated with refractory systemic lupus erythematosus4
Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis4
VEXAS syndrome4
Epigenetic regulation by ASXL1 in myeloid malignancies4
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges4
Histidine decarboxylase deficiency inhibits NBP-induced extramedullary hematopoiesis by modifying bone marrow and spleen microenvironments4
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute4
Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan4
Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation4
Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation4
Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group4
Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis4
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy4
Isolated thrombosis after COVID-19 vaccination: case series4
Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis4
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation4
The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study4
Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance4
Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A4
Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases4
A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation4
Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies4
Novel technologies for improving the safety and efficacy of CAR-T cell therapy4
Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan4
Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease4
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor4
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation4
Quality of life and patient-reported outcomes in chronic severe neutropenia conditions4
Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation4
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism4
Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy4
Phenotype-oriented anticoagulant therapy for sepsis: still a work in progress4
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial4
A novel germline GATA2 frameshift mutation with a premature stop codon in a family with congenital sensory hearing loss and myelodysplastic syndrome4
Acquired hypofibrinogenemia in a patient with multiple myeloma4
Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma4
Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion4
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial4
Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis4
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma4
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day4
Relationship between serum zinc level and sepsis-induced coagulopathy4
MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia4
Decreased LAG3 expression on T effector cells and regulatory T cells in SAA4
Acute myeloid leukemia during pregnancy: a single institutional experience with 17 patients and literature review4
Reference intervals of red blood cell parameters and platelet count for healthy adults in Japan4
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency4
Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan4
The clinical application of SNP-based next-generation sequencing (SNP-NGS) for evaluation of chimerism and microchimerism after HLA-mismatched stem cell microtransplantation4
Expert consensus regarding standardization of sample preparation for clotting time assays4
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marke4
Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line4
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine4
High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-4
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient4
FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children’s Cancer Group4
0.049953937530518